NEWS
Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis
Palisade Bio (NASDAQ: PALI) has presented positive data from two ex vivo translational studies of PALI-2108, their colon-specific PDE4 inhibitor prodrug for ulcerative colitis treatment. The studies demonstrated successful bioactivation in stool samples and significant TNFα inhibition in whole blood. PALI-2108achieved a 90.1% conversion rate at 24 hours and showed 20-fold higher potency compared to apremilast. The drug's targeted activation in the colon aims to minimize systemic exposure and side effects. The company plans to initiate Phase 1 clinical trials before year-end, including studies with healthy volunteers and UC patients.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2538Followers
107Following
28KVisitors
Follow